Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)

Darmawan D.; Rengganis I.; Rumende C.M.; Shatri H.; Koesnoe S.; Umbarawan Y.; Putranto R.; Nasution S.A.
Darmawan, Danny (58976408900); Rengganis, Iris (8449988000); Rumende, Cleopas Martin (14325966300); Shatri, Hamzah (28767986500); Koesnoe, Sukamto (26028015000); Umbarawan, Yogi (57196077830); Putranto, Rudi (56074051000); Nasution, Sally Aman (57189373134)
58976408900; 8449988000; 14325966300; 28767986500; 26028015000; 57196077830; 56074051000; 57189373134
Effecti veness and Safety of Nebul i zed Magnesi um as Last Line Treatment in Adults with Acute Asthma Attack: A Systematic Review and Meta-Analysis
2024
Acta Medica Indonesiana
56
1
3
12
9
0
Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Division of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo, Jakarta, Indonesia; Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo, Jakarta, Indonesia
Darmawan D., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rengganis I., Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rumende C.M., Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Shatri H., Division of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo, Jakarta, Indonesia; Koesnoe S., Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Umbarawan Y., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Putranto R., Division of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo, Jakarta, Indonesia; Nasution S.A., Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo, Jakarta, Indonesia
Background: Asthma is a disease characterized by chronic airway inflammation, however one-third of asthmatic cases did not respond adequately. Inhaled magnesium has been proposed as a treatment for unresponsive asthma cases. However, its role remains controversial. This review evaluates the effectiveness and safety of nebulized magnesium compared to standard therapy (Beta Agonist, Anticholinergic, Corticosteroid) in adults with acute asthma attacks. Methods: The protocol has been registered in PROSPERO. A literature search was conducted through PubMed/MEDLINE, Cochrane, ProQuest, and Google Scholar, and using the keywords “inhaled magnesium” and “asthma”. Manual searches were carried out through data portals. Journal articles included are randomized controlled trials. The assessment risk of bias was performed using Version 2 of the Cochrane risk-of-bias tool for randomized trials. Results: There are five articles included in this review. There is no significant difference in readmission rate and oxygen saturation in the magnesium group compared to control (RR 1; 95% CI 0.92 to 1,08; p= 0,96 and MD 1,82; 95% CI-0.89 to 4.53; p= 0.19, respectively). There is a significant reduction of respiratory rate and clinical severity in magnesium (MD-1,72; 95% CI-3,1 to 0.35; p= 0.01, RR 0.29; 95% CI 0.17 to 0.69; p <0.001, respectively). There was a higher risk of side effects in the magnesium group (HR 1.56; 95%CI 1.05 to 2.32; p= 0.03). However, the side effects are relatively mild such as hypotension and nausea. Conclusion: Inhaled magnesium improves the outcome of asthmatic patients, especially in lung function, clinical severity, and respiratory rate. Moreover, inhaled magnesium is safe to be given. © 2024, Indonesian Society of Internal Medicine. All rights reserved.
Adult; Asthma; Inhaled Magnesium
Adult; Anti-Asthmatic Agents; Asthma; Drug Therapy, Combination; Hospitalization; Humans; Magnesium; antiasthmatic agent; magnesium; adult; asthma; combination drug therapy; hospitalization; human; meta analysis
Indonesian Society of Internal Medicine
01259326
38561891
Article
Q3
282
15714